Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Diphenyl Urea Compounds Inhibit Growth of Tuberculosis Bacteria

By LabMedica International staff writers
Posted on 13 Dec 2010
Using advanced genetic engineering techniques to produce enzymes from tuberculosis-causing Mycobacterium in Escherichia coli, researchers have identified a series of chemical compounds that inhibit the recombinant form of an essential enzyme.

Investigators at the University of Birmingham (United Kingdom) used plasmid technology to transfer the three Mycobacterium genes that code for the enzyme inosine monophosphate dehydrogenase (IMPDH) into cultures of E. More...
coli. They found that of the three enzyme isoforms only one, Mt-Guab2, was active in M. tuberculosis at an optimum pH of 8.5 and temperature of 37 °C. The investigators then used recombinant Mt-Guab2 to screen for potential inhibitory drugs.

The Investigators reported in the November 16, 2010, online edition of the journal Microbiology that from a group of 16 diphenyl urea (DPU) compounds, 3 were found to inhibit IMPDH. When tested against living Mycobacterium, these compounds prevented growth of both M. tuberculosis and M. smegmatis. When a plasmid overexpressing the Mt-Guab2 gene was implanted into M. smegmatis, 16 times the amount of DPU was required to inhibit growth.

"IMPDH is essential for cells to proliferate rapidly, which is one of the characteristics of microbial infection as well as human cancers. IMPDH has been used as a target in some anticancer drugs, as blocking the enzyme can prevent proliferation of the cell and induce cell death. Our findings show that inhibiting the bacterial version of IMPDH is a strategy that could be exploited for anti-TB drugs," said senior author Dr. Gurdyal Besra, professor of physiology and chemistry at the University of Birmingham. "The DPU compounds we tested have selective activity against Mycobacterium species, meaning that any future drugs based on these would be specific and would not affect human cells.”

"In the face of growing resistance to current therapies, we desperately need new treatments for TB that are safe and effective,” said Dr. Besra. "We are tapping the potential of a so far unexploited target which could lead to the synthesis of a novel antitubercular drug and our findings, so far are extremely encouraging.”

Related Links:
University of Birmingham



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.